Latest news with #MSD
NZ Herald
11 hours ago
- Business
- NZ Herald
Buzzing in Ōmokoroa
Vague Hippo owner Haydee DeKlerk, 32, from Ōmokoroa, created a New Zealand-first frozen espresso pod company, after six years with the MSD.
NZ Herald
a day ago
- Health
- NZ Herald
Chronic illness patient finds home after long wait in Northland
Logan, who is steroid-dependent and lives with only one functioning lung, said his doctors gave him a two-year life expectancy. 'But that's what they're giving me,' he said. 'I know I'm going to live longer than that. That's my plan.' He's now finally been placed in a warm, dry Kāinga Ora home in Kaitāia. 'I was pushing and pushing because the way I was living, with my health condition, was why I kept ending up in hospital,' he said. Kaitaia resident Zaine Logan is happy in his new home after a long wait. Photo / Yolisa Tswanya Logan says the stress of his housing situation was overwhelming. For a time, he lived with a cousin in a location that ambulances struggled to access. 'Where I lived with my cousin wasn't the best, it was hard for the ambulance to access me and I was always under a bit of stress because I knew how long it would take the ambulance to get there. It was a scary way to live. I was always wondering, 'am I going to die tomorrow?'.' After one of his more recent hospitalisations, he said a doctor refused to discharge him until he had a place to stay. Now, as he slowly moves his belongings into his new place, Logan said it's starting to feel like a home. 'It's warm, it's peaceful, and that's all I ever wanted from the start. I'm just happy that I've got somewhere of my own.' He said he was grateful his doctors wrote a letter and believed that was the push that led him to having his home. Graham MacPherson, MSD regional commissioner for Northland, said the supply of public housing was very tight and there was a shortage of affordable housing across the country. 'At any given time, we have many people, often with high needs and complex situations, looking for housing. How quickly they are housed depends both on their need and what is available that matches that need.' MacPherson said Logan was placed on the Housing Register on December 23, 2024 with a priority rating of A19 – which reflected his high level of need. 'At that same appointment we provided Zaine with financial support to stay in accommodation in Kaitāia. 'In March 2025 we attempted to contact Zaine about his Social Housing Application, but we were unable to reach him. As a result, his application was put on hold.' He added that in early June 2025 Logan approached them again requesting help with housing as his circumstances had changed. 'We offered to refer him to Transitional Housing but he declined and elected to stay with a friend.' Logan said he declined the transitional housing accommodation as he was not happy with the conditions of the place offered, opting to stay with his cousin instead. On June 24 he was offered a social housing property with Kāinga Ora. Kāinga Ora is responsible for matching people to available housing. Jeff Murray, regional director, Northland, said Logan was matched with a home in January this year and came back to their attention in June. 'Zaine's application came to our attention again in early June. Soon after, a home became available in Kaitāia that Zaine was matched to. We were able to contact Zaine, and he was offered the home as per our usual processes.'
Business Wire
7 days ago
- Business
- Business Wire
Merck Announces Fourth-Quarter 2025 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Globe and Mail
7 days ago
- Business
- Globe and Mail
Merck Announces Fourth-Quarter 2025 Dividend
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Irish Post
20-07-2025
- Business
- Irish Post
British-based accountancy firm makes inroads into Ireland after partnering with Dublin company
A BRITISH-BASED accountancy firm has announced its first partnership in Ireland as part of wider plans to allow its British-based clients to trade in Europe. DJH was founded in 2021 with the merger of two Staffordshire firms and has since made 15 acquisitions to become a multidisciplinary team of 670 people across England. MSD Accountants in Dublin has now joined the group, providing a strong link into Britain for the Irish firm's own clients already operating there. "It is fantastic to be joining the DJH group and all the additional expertise, enhanced capabilities and international reach that comes with it," said MSD Managing Partner Richard Daly. "The two businesses share similar values of trust, transparency, quality and client service. "Joining DJH will benefit our existing clients through enhanced infrastructure and, for our clients operating in the UK, we will now have a full-service integrated offering there." Formed in 1990, MSD provides expertise in advisory, assurance, business support services and tax to subsidiaries of multinationals, mid-size private companies, family businesses and large organisations operating across multiple jurisdictions. Its team work across a range of sectors, including professional services, entertainment, hospitality, construction, automotive, distribution, IT and communications. Daly will continue to lead the team alongside fellow partner, Brendan Murtagh, and clients will continue to be supported by the 30-strong team at their Santry Business Park offices. 'Attractive access point' DJH is a top 40 British accountancy and professional services group that has ambitions to break into the top 20 within the next four years. Having acquired its first office in Ireland, the company wants to increase organic growth with MSD by extending services to existing clients and attracting new ones. It sees the Dublin firm as a 'perfect fit' to allow it to offer services to British-based clients looking to expand into Europe. "Dublin is one of the most significant financial hubs in Europe, with a strong economy, favourable corporate tax rate and, post-Brexit, it has become an increasingly attractive access point for UK firms looking to trade with the EU," said James Beardmore, COO of DJH. "We've aspired to have a presence in the city for a long time and MSD Accountants is the perfect fit, with its reputation for fantastic service and specialisms in several aligned sectors for us. "Importantly, it gives DJH multinational service capability and EU regulatory compliance for UK clients looking at cross-border planning, tax efficient structures and expanding their European operations through an Irish presence." Beardmore also believes further acquisitions in Ireland will follow on from the MSD deal. "The partnership also gives us the perfect platform to target more M&A activity in Ireland," he said. See More: DJH, Dublin, MSD Accountants
